Neonatal community-acquired pneumonia: Pathogens and treatment

被引:9
|
作者
Wang, Hua [1 ]
Tang, Jun [1 ]
Xiong, Ying [1 ]
Li, Xihong [1 ]
Gonzalez, Fernando [2 ]
Mu, Dezhi [1 ,2 ]
机构
[1] Sichuan Univ, W China Univ Hosp 2, Dept Pediat, Chengdu 610041, Peoples R China
[2] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA
关键词
community-acquired pneumonia; drug sensitivity; neonate; pathogen; INFECTIONS; ETIOLOGY; DIAGNOSIS; CHILDREN; AGENTS; RATES;
D O I
10.1111/j.1440-1754.2010.01814.x
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Aim: To analyse the bacterial pathogens and drug sensitivities for neonatal community-acquired pneumonia. Methods: Seven hundred sixty sputum samples from newborns with community-acquired pneumonia were cultured to determine microbial organisms present and their drug sensitivities. Results: Of the 760 specimens, 425 grew pathogens for a 55.9% positive rate. Among the 425 positive cultures, 278 grew gram-negative organisms (65.4%), 142 grew gram-positive organisms (33.3%), while 5 grew fungus (1.3%). The most common gram-negative organisms were Escherichia coli, Klebsiella pneumoniae and Hemophilus influenzae, while the most common gram-positive organisms were Staphylococcus aureus, Staphylococcus epidermidis and Staphylococcus haemolyticus. To the gram-negative organisms, the most sensitive drugs were meropenem, imipenem and amikacin, while to the gram-positive ones were vancomycin, teicoplanin and quinupristin/dalfopristin. Conclusions: The most common causative bacteria were gram-negative organisms, which were highly sensitive to Meropenem, Imipenem and Amikacin, yet often treatable with more focused antibiotic coverage, which depended on the bacterium identified.
引用
收藏
页码:668 / 672
页数:5
相关论文
共 50 条
  • [41] Levofloxacin in the treatment of community-acquired pneumonia
    Noreddin, Ayman M.
    Elkhatib, Walid F.
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2010, 8 (05) : 505 - 514
  • [42] Levofloxacin in the treatment of community-acquired pneumonia
    Léophonte, P
    Veyssier, P
    PRESSE MEDICALE, 1999, 28 (36): : 1975 - 1979
  • [43] Linezolid in the treatment of community-acquired pneumonia
    Kaplan, SL
    Patterson, L
    Edwards, KM
    Azimi, PH
    Bradley, JS
    Blumer, JL
    Lobeck, FG
    Stalker, DJ
    Anderson, DC
    PEDIATRIC RESEARCH, 2000, 47 (04) : 266A - 266A
  • [44] Asthma in children with community-acquired pneumonia caused by atypical pathogens
    Nesterenko, Z.
    Ivanina, O.
    ALLERGY, 2010, 65 : 634 - 634
  • [45] Severe Community-Acquired Pneumonia (CAP) due to Atypical Pathogens
    Michalopoulos, Argyris
    Rizos, Michael
    Falagas, Matthew E.
    CURRENT RESPIRATORY MEDICINE REVIEWS, 2005, 1 (03) : 265 - 271
  • [46] Diagnosing Viral and Atypical Pathogens in the Setting of Community-Acquired Pneumonia
    Waterer, Grant W.
    CLINICS IN CHEST MEDICINE, 2017, 38 (01) : 21 - +
  • [47] Linezolid eradicates common pathogens in outpatients with community-acquired pneumonia
    Cammarata, SK
    Hempsall, KA
    Oliphant, TH
    Todd, WM
    Hafkin, B
    CLINICAL INFECTIOUS DISEASES, 2000, 31 (01) : 225 - 225
  • [48] Community-acquired pneumonia. Common pathogens and antimicrobial resistance
    Pletz, M. W. R.
    PNEUMOLOGE, 2005, 2 (01): : 17 - 27
  • [49] Community-Acquired Pneumonia with Risk for Drug-Resistant Pathogens
    Fleming, Virginia
    Buck, Brian
    Nix, Nancy
    Kumar, Parag
    Southwood, Robin
    SOUTHERN MEDICAL JOURNAL, 2013, 106 (03) : 209 - 216
  • [50] Community-acquired pneumonia in Europe: causative pathogens and resistance patterns
    Woodhead, M
    EUROPEAN RESPIRATORY JOURNAL, 2002, 20 : 20S - 27S